posted
ULURU Receives First U.S. Army SBIR Funding; Partnered with University of Texas Southwestern Medical Center to Develop Nanoparticle Aggregate Technology Business Wire - November 16, 2005 14:19
DALLAS, Nov 16, 2005 (BUSINESS WIRE) -- ULURU INC. ("ULURU") who has signed a definitive merger agreement with Oxford Ventures, Inc. (OTC Bulletin Board: OXFV) today announced the receipt of funding for a Department of Defense SBIR Phase I Grant award.
The U.S. Army SBIR Program awarded to ULURU funding for the proposal titled, "Chemical Casualty Care: Hydrogel Nanoparticle Aggregates as Wound Dressings Following Debridement of Cutaneous Vesicant Injuries." The Phase I SBIR Proposal has a period of performance of six months from November 14, 2005 to June 13, 2006.
ULURU is partnered with the Department of Plastic Surgery at the University of Texas Southwestern Medical School (UTSW) in Dallas. UTSW will provide preclinical and clinical direction in the development of this platform nanoparticle aggregate technology as a standard of care for chemically burned tissue regeneration. The objective of the Phase I proposal is to achieve an optimal nanoparticle aggregate wound dressing design based on in vitro and in vivo proof-of-concept experiments. We believe that our relationship with UTSW maximizes the potential for advantages of this technology to be translated into clinical benefits through the design and testing of our technology in appropriate wound healing models. These studies will compare the nanoparticle aggregate system with standard dressings. Commenting on the SBIR award and relationship between UTSW and Uluru, Spencer Brown, PhD, Director of Research, Nancy Lee & Perry Bass Advanced Wound Healing Laboratory in the Department of Plastic Surgery at UTSW states that, "This award provides for the development of a new generation of wound dressings using Uluru's novel, platform technology. The materials that provide the best care for surgical patients will be identified through an advanced, evidence-based process."
In conjunction with UTSW, ULURU has initiated in vivo studies in a burn-healing model and these data will form the basis for a $1 million fast-track Phase II SBIR Grant proposal to clinically develop and demonstrate the efficacy of a wound dressing. Phase II funding will therefore involve extensive human clinical trials under the guidance of the Department of Plastic Surgery at UTSW Medical School.
Commenting on the UTSW relationship Kerry P. Gray, President and CEO of ULURU stated, "We are delighted to be collaborating with the UTSW Department of Plastic Surgery, which is one of the premier groups in this field in the United States. We believe that utilizing their capabilities significantly enhances the potential for the development of products utilizing our nanoparticle aggregate technology in burn care, wound management and as dermal fillers."
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of topical delivery technologies to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate Technology.
SOURCE: ULURU Inc.
ULURU Inc. Kerry P. Gray, 214-905-5145
-------------------- EVERY Day ABOVE GROUND is a GREAT DAY!!!
IP: Logged |
posted
Here it is, please dont thank me I'M PI**ED OFF
OXFV: Reverse Split 1:400 to be voted on 12/19
DEAR SHAREHOLDERS: Notice is hereby given that Oxford Ventures, Inc., a Nevada corporation (the "Company"), pursuant to the Bylaws of the Company, will hold a special stockholders' meeting (the "Special Meeting") to be held at the offices of the Company's special counsel, Gottbetter & Partners, LLP, at 488 Madison Avenue, New York, New York 10022 on December 19 2005 at eleven o'clock in the morning, Eastern Time: (1) To amend our Certificate of Incorporation substantially in the form of Exhibit 1 to effect a reverse stock split (the "Stock Split") of our common stock of one share, with a par value of $0.001, for four-hundred shares outstanding so that every four-hundred outstanding shares of common stock before the Stock Split shall represent one share of common stock, with a par value of $0.001, after the Stock Split with all fractional shares rounded up to the next whole share. (2) Upon completion of the Stock Split, to amend our Certificate of Incorporation substantially in the form of Exhibit 1 to decrease the amount of authorized capital from 400,000,000 shares of common stock, $.001 par to 200,000,000 shares of common stock, $.001 par value, and to authorize the issuance of up to 20,000 shares of Preferred Stock, par value $0.001 per share (the "Share Amendment"). (3) To adopt the Uluru Inc. 2005 Equity Incentive Plan (the "Plan"), substantially in the form of Exhibit 2, pursuant to which our board of directors is given the ability to provide incentives through the issuance of options, stock, restricted stock, and other stock-based awards, representing up to 2,000,000 share of the Company's common stock, to certain employees, directors, officers and non-employee service providers. (4) To amend our Certificate of Incorporation substantially in the form of Exhibit 3 to change our name from Oxford Ventures, Inc. to Uluru Inc. (the "Name Change") contingent upon the completion of the merger between Uluru Inc. and Uluru Acquisition Corp. (5) To appoint Kerry P. Gray, William W. Crouse, Jeffery B. Davis and Dr. David Reese as the Company's directors (the "Director Appointments").
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Razz]](tongue.gif)
![[Smile]](smile.gif)
![[Mad]](mad.gif)
Here it is, please dont thank me I'M PI**ED OFF
